Nintedanib: A novel therapeutic agent for pulmonary fibrosis

Nintedanib: A novel therapeutic agent for pulmonary fibrosis

Bibliographic Details
Main Authors:	Arpita Singh, Ajay Kumar Verma, Jyoti Bajpai, Ved Prakash, Surya Kant, Ankit Bhatia
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-01-01
Series:	MAMC Journal of Medical Sciences
Online Access:	http://www.mamcjms.in/article.asp?issn=2394-7438;year=2015;volume=1;issue=3;spage=172;epage=173;aulast=Singh

Similar Items

Coexistence of leprosy and pulmonary tuberculosis: An uncommon entity
by: Ajay Kumar Verma, et al.
Published: (2015-01-01)

A search for covert precipitating clinical parameters in frequent exacerbators of chronic obstructive pulmonary disease
by: Ankit Bhatia, et al.
Published: (2016-01-01)

Indacaterol: A novel, Inhaled Beta-2 agonist for COPD
by: Ved Prakash, et al.
Published: (2015-01-01)

Nintedanib in the treatment of idiopathic pulmonary fibrosis
by: Mariano E. Mazzei, et al.
Published: (2015-06-01)

Is nintedanib effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres
Published: (2017-06-01)

ORALAIR: A novel sublingual immunotherapy
by: Arpita Singh, et al.
Published: (2016-01-01)

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]
by: Andrea Belisari, et al.
Published: (2017-04-01)

An unusual source of septic pulmonary embolism: Perianal abscess in an immunocompetent patient
by: Ved Prakash, et al.
Published: (2015-01-01)

Tubercular round pneumonia simulating a mass lesion in an adult
by: Ved Prakash, et al.
Published: (2018-01-01)

Pulmonary artery pseudoaneurysm: An uncommon fatal complication associated with tubercular empyema
by: Ved Prakash, et al.
Published: (2015-01-01)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
by: Hee-Young Yoon, et al.
Published: (2018-10-01)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
by: Luca Richeldi, et al.
Published: (2020-01-01)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
by: Ryosuke Imai, et al.
Published: (2020-03-01)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
by: Christopher J. Ryerson, et al.
Published: (2019-04-01)

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
by: Hiroaki Ogata, et al.
Published: (2021-05-01)

Traumatic esophageopleural fistula due to fish bone injury
by: Ajay Kumar Verma, et al.
Published: (2015-01-01)

Oral tuberculosis mimicking malignancy
by: Ajay Kumar Verma, et al.
Published: (2015-01-01)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis.
by: Masahiro Nemoto, et al.
Published: (2021-01-01)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01)

Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
by: Yusuke Ochi, et al.
Published: (2020-10-01)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
by: Claudia Valenzuela, et al.
Published: (2020-01-01)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
by: Jai B Mullerpattan, et al.
Published: (2019-01-01)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
by: Bonella F, et al.
Published: (2015-12-01)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
by: Osamu Nishiyama, et al.
Published: (2021-08-01)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
by: Woodcock HV, et al.
Published: (2013-06-01)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01)

Sarcomatoid Lung Carcinoma-A Rare Entity
by: Jyoti Bajpai, et al.
Published: (2018-05-01)

Effects of Nintedanib in an Animal Model of Liver Fibrosis
by: Lutz Wollin, et al.
Published: (2020-01-01)

Primary Multidrug-Resistant Extrapulmonary Tuberculosis Presenting as Empyema Necessitans in an Immuno-competent Young Girl
by: Jyoti Bajpai, et al.
Published: (2017-10-01)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
by: Pilar Rivera-Ortega, et al.
Published: (2018-09-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
by: Abe M, et al.
Published: (2018-10-01)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
by: Sophie V. Fletcher, et al.
Published: (2018-10-01)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
by: Ian Glaspole, et al.
Published: (2021-04-01)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
by: Jaume Bordas-Martinez, et al.
Published: (2021-01-01)

Adenocarcinoma lung presenting as multiple cutaneous metastasis: A rare initial presentation of lung carcinoma
by: Ved Prakash, et al.
Published: (2015-01-01)

Study of oxidative stress biomarkers in chronic obstructive pulmonary disease and their correlation with disease severity in north Indian population cohort
by: Jyoti Bajpai, et al.
Published: (2017-01-01)

Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
by: Masahiro Tahara, et al.
Published: (2019-08-01)

Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
by: Yutaka Umemura, et al.
Published: (2021-07-01)

Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis
by: Wei-Chih Chen, et al.
Published: (2020-07-01)